摘要
ABSTRACT To evaluate the effect of bevacizumab on cerebral ischemia, we used 2-deoxy-2-18F-fluoro-D-glucose （18F-FDG） small-animal positron emission tomography （PET） in the middle cerebral artery occlusion （MCAO） rat model. After baseline neurologic function tests and PET studies, MCAO Sprague-Dawley rats received bevacizumab or normal saline （controls）. Weekly PET imaging and neurologic function tests showed that the 18F-FDG accumulation in the bevacizumab group was similar to that in the controls during the first 2 weeks, but lower than in controls at weeks 3 and 4. However, no difference was found in neurological scores between the groups. The number of von Willebrand factor-positive cells in the bevacizumab group was lower than that in controls. The expression of vascular endothelial growth factor was higher than in controls at week 4. These results suggested that bevacizumab does not influence functional recovery in this model of cerebral ischemia during a 4-week period, but inhibits vascular formation and metabolic recovery, which may be considered in cancer patients with a recent ischemic stroke.
ABSTRACT To evaluate the effect of bevacizumab on cerebral ischemia, we used 2-deoxy-2-18F-fluoro-D-glucose （18F-FDG） small-animal positron emission tomography （PET） in the middle cerebral artery occlusion （MCAO） rat model. After baseline neurologic function tests and PET studies, MCAO Sprague-Dawley rats received bevacizumab or normal saline （controls）. Weekly PET imaging and neurologic function tests showed that the 18F-FDG accumulation in the bevacizumab group was similar to that in the controls during the first 2 weeks, but lower than in controls at weeks 3 and 4. However, no difference was found in neurological scores between the groups. The number of von Willebrand factor-positive cells in the bevacizumab group was lower than that in controls. The expression of vascular endothelial growth factor was higher than in controls at week 4. These results suggested that bevacizumab does not influence functional recovery in this model of cerebral ischemia during a 4-week period, but inhibits vascular formation and metabolic recovery, which may be considered in cancer patients with a recent ischemic stroke.
基金
supported by grants from the National Basic Research Development Program of China(2014CB744505)
the National Natural Science Foundation of China(81101023, 81173468,and 81101835)
Natural Science Foundation of Zhejiang Province,China(Z2110230 and Y2110299)
the Health Bureau of Zhejiang Province,China(2010ZA075 and 2011ZDA013)
the Science and Technology Bureau of Zhejiang Province,China (2012R10040)
